CD19 and B-cell non-Hodgkin lymphoma: With this in mind, clinical trials are currently underway combining the treatment of B-cell lymphomas or leukemias with the anti-CD19 BiTE®, Blincyto®, with anti-PD-1 [139,140] or anti-PD-1 and anti-CTLA4 antibodies [141].